Cancer is a disease of aging and, as the world's population ages, the number of older
persons with cancer is increasing and will make up a growing share of the oncology …

Generating evidence on the use, effectiveness, and safety of new cancer therapies is a
priority for researchers, health care providers, payers, and regulators given the rapid pace of …

ABSTRACT Background and Objective The Surveillance, Epidemiology, and End Results
Program (SEER) program and the National Program of Cancer Registries (NPCR), are …

Importance For patients with advanced non–small cell lung cancer (NSCLC) treated with
frontline immunotherapy-based treatment, the optimal duration of immune checkpoint …

Abstract On April 4, 2019, the FDA approved a supplemental new drug application for
palbociclib (IBRANCE), to expand the approved indications in women with hormone …

Background Anti-programmed cell death protein (death-ligand) 1 [PD-(L) 1] therapy alone
[cancer immunotherapy (CIT)-mono] or combined with platinum-based chemotherapy (CIT …

Background Despite the rapid adoption of immunotherapies in advanced non–small cell
lung cancer (advNSCLC), knowledge gaps remain about their real‐world (rw) performance …

Randomized controlled trials are the gold standard to investigate efficacy and safety of new
treatments. In certain settings, however, randomizing patients to control may be difficult for …

Objective To assess large language models on their ability to accurately infer cancer
disease response from free-text radiology reports. Materials and Methods We assembled 10 …

Background Mutations in STK11 (STK11 m) and frequently co-occurring KRAS mutations
(KRAS m/STK11 m) are associated with poor survival in metastatic NSCLC (mNSCLC) …